Pillstats
Rx only · Tablet · Oral

Ubrogepant

Brands: Ubrelvy · Ubrogepant

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)2268216
US makers1 labelers
Packages9
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$31.38$62.76$94.14$125.52Dec 2025May 2026Jul 2026
$109.089
Latest avg · Jul 22, 2026
+5%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

52K103K155K207K2025 Q12025 Q22025 Q32025 Q42026 Q1
174K
Rx · 2026 Q1
2.0M
Units dispensed
+13%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Allergan, Inc.unknown9SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.